AI assistant
GlaxoSmithKline PLC — Director's Dealing 2017
Apr 25, 2017
5262_dirs_2017-04-25_ee321c52-d643-4605-8e8c-b8f4c69c33ba.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 2797D
GlaxoSmithKline PLC
25 April 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2017.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| $41.1461 | 19.456 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2017-04-24
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2017.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| $41.1461 | 230.514 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2017-04-24
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 April 2017.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| $41.1461 | 1,810.730 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2017-04-24
f)
Place of the transaction
New York Stock Exchange (XNYS)
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLELFLDZFZBBX